Kite, a Gilead Company announced that the FDA has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma… read more.
Gilead Sciences, Inc. announced new, long-term data from open-label extensions (OLE) of two Phase III studies (Study 1489 and Study 1490) of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
